EZB-type Diffuse Large B-cell Lymphoma Cell Lines Have Superior Migration Capabilities Compared to MCD-type

Overview

Journal Br J Haematol

Specialty Hematology

Date 2024 Oct 2

PMID 39355919

Authors

Marwa Sherif

Hendrik Schafer

Sonja Scharf

Vivienne van Oostendorp

Aresu Sadeghi Shoreh Deli

Andreas G Loth

Matthieu Piel

Martin-Leo Hansmann

Thomas Oellerich

Falko Fend

Leticia Quintanilla-Martinez

Sylvia Hartmann

Affiliations

Soon will be listed here.

Abstract

Diffuse large B-cell lymphoma (DLBCL) represents the most prevalent aggressive B-cell lymphoma. The group is heterogeneous and the outcome is variable. A variety of approaches have been employed with the objective of improving the stratification of DLBCL patients according to their prognosis, based on the cell of origin. Recently, distinct genetic subtypes of DLBCL have been identified. Given the importance of cell migration in immune cells, the objective of this study was to ascertain whether different genetic subtypes of DLBCL exhibit disparate migration abilities. MCD- and EZB-type DLBCL cell lines were subjected to testing to ascertain their basal velocity in straight microchannels and their ability to overcome tight constrictions of 2 μm. The EZB-type cell lines showed superior basal migration velocity and constriction passage time, and a similar trend was observed in live cell imaging of native human DLBCL tissue. In addition, MCD-type DLBCL exhibited significantly elevated levels of nuclear lamin A/C, which is responsible for the stiffness of the nuclear envelope and could thus explain the disparate migration behaviours observed among these subtypes. Our study suggests that different genetic subtypes of DLBCL may not only influence the outcome after therapy but also the motility of the tumour cells.

Citing Articles

EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type.

Sherif M, Schafer H, Scharf S, van Oostendorp V, Sadeghi Shoreh Deli A, Loth A Br J Haematol. 2024; 205(6):2327-2337.

PMID: 39355919 PMC: 11637725. DOI: 10.1111/bjh.19778.

References

Chapuy B, Stewart C, Dunford A, Kim J, Kamburov A, Redd R . Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018; 24(5):679-690. PMC: 6613387. DOI: 10.1038/s41591-018-0016-8. View

Liu Y, Zhou X, Wang X . Targeting the tumor microenvironment in B-cell lymphoma: challenges and opportunities. J Hematol Oncol. 2021; 14(1):125. PMC: 8369706. DOI: 10.1186/s13045-021-01134-x. View

Ennishi D, Healy S, Bashashati A, Saberi S, Hother C, Mottok A . TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma. Nat Med. 2020; 26(4):577-588. PMC: 8480332. DOI: 10.1038/s41591-020-0757-z. View

Feng M, Huang B, Du Z, Xu X, Chen Z . DLC-1 as a modulator of proliferation, apoptosis and migration in Burkitt's lymphoma cells. Mol Biol Rep. 2010; 38(3):1915-20. DOI: 10.1007/s11033-010-0311-z. View

Wang Y, Tan J, Wu H, Yi C . High Glucose Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in A20 Murine Diﬀuse Large B-Cell Lymphoma Cells Through Increased Expression of High Mobility Group AT-Hook 2 (HMGA2). Med Sci Monit. 2019; 25:3860-3868. PMC: 6545067. DOI: 10.12659/MSM.916195. View

Dou A, Wang Z, Zhang N, Liu J . Loss of Reelin suppresses cell survival and mobility in non-Hodgkin lymphoma. Oncol Rep. 2017; 37(6):3572-3580. DOI: 10.3892/or.2017.5626. View

Ding N, Ping L, Feng L, Zheng X, Song Y, Zhu J . Histone deacetylase 6 activity is critical for the metastasis of Burkitt's lymphoma cells. Cancer Cell Int. 2014; 14(1):139. PMC: 4276069. DOI: 10.1186/s12935-014-0139-z. View

Xing X, Xu T, Liu B, Guo Q . LncRNA SNHG5 can Regulate the Proliferation and Migration of Diffuse Large B Cell Lymphoma Progression via Targeting miR-181-5p/XIAP. J Cancer. 2022; 13(3):784-792. PMC: 8824899. DOI: 10.7150/jca.60521. View

Heuze M, Collin O, Terriac E, Lennon-Dumenil A, Piel M . Cell migration in confinement: a micro-channel-based assay. Methods Mol Biol. 2011; 769:415-34. DOI: 10.1007/978-1-61779-207-6_28. View

10.

Roschewski M, Staudt L, Wilson W . Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol. 2013; 11(1):12-23. PMC: 7709161. DOI: 10.1038/nrclinonc.2013.197. View

11.

Alizadeh A, Eisen M, Davis R, Ma C, Lossos I, Rosenwald A . Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature. 2000; 403(6769):503-11. DOI: 10.1038/35000501. View

12.

Sherif M, Schafer H, Scharf S, van Oostendorp V, Sadeghi Shoreh Deli A, Loth A . EZB-type diffuse large B-cell lymphoma cell lines have superior migration capabilities compared to MCD-type. Br J Haematol. 2024; 205(6):2327-2337. PMC: 11637725. DOI: 10.1111/bjh.19778. View

13.

Schmitz R, Wright G, Huang D, Johnson C, Phelan J, Wang J . Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma. N Engl J Med. 2018; 378(15):1396-1407. PMC: 6010183. DOI: 10.1056/NEJMoa1801445. View

14.

Hartmann S, Scharf S, Steiner Y, Loth A, Donnadieu E, Flinner N . Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas. Cancers (Basel). 2021; 13(20). PMC: 8534096. DOI: 10.3390/cancers13205208. View

15.

Fowler N, Cheah C, Gascoyne R, Gribben J, Neelapu S, Ghia P . Role of the tumor microenvironment in mature B-cell lymphoid malignancies. Haematologica. 2016; 101(5):531-40. PMC: 5004369. DOI: 10.3324/haematol.2015.139493. View

16.

Jin W, Wang X . PLAGL2 Promotes the Proliferation and Migration of Diffuse Large B-cell Lymphoma Cells via Wnt/β-catenin Pathway. Ann Clin Lab Sci. 2022; 52(3):359-366. View

17.

Wright G, Huang D, Phelan J, Coulibaly Z, Roulland S, Young R . A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications. Cancer Cell. 2020; 37(4):551-568.e14. PMC: 8459709. DOI: 10.1016/j.ccell.2020.03.015. View

18.

Verdiere L, Mourcin F, Tarte K . Microenvironment signaling driving lymphomagenesis. Curr Opin Hematol. 2018; 25(4):335-345. DOI: 10.1097/MOH.0000000000000440. View

19.

Lenz G, Wright G, Dave S, Xiao W, Powell J, Zhao H . Stromal gene signatures in large-B-cell lymphomas. N Engl J Med. 2008; 359(22):2313-23. PMC: 9103713. DOI: 10.1056/NEJMoa0802885. View

20.

Bein J, Flinner N, Haupl B, Mathur A, Schneider O, Abu-Ayyad M . T-cell-derived Hodgkin lymphoma has motility characteristics intermediate between Hodgkin and anaplastic large cell lymphoma. J Cell Mol Med. 2022; 26(12):3495-3505. PMC: 9189347. DOI: 10.1111/jcmm.17389. View